Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma
- PDF / 1,785,519 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 198 Views
CELL LINE
Establishment and characterization of NCC‑PLPS1‑C1, a novel patient‑derived cell line of pleomorphic liposarcoma Rei Noguchi1 · Yuki Yoshimatsu1 · Takuya Ono1 · Akane Sei1 · Kaoru Hirabayashi2 · Iwao Ozawa3 · Kazutaka Kikuta4 · Tadashi Kondo1 Received: 29 August 2020 / Accepted: 5 November 2020 © Japan Human Cell Society 2020
Abstract Pleomorphic liposarcoma (PLPS) is a rare subtype of liposarcoma, characterized by the presence of pleomorphic lipoblasts without definitive molecular aberrations; it accounts for less than 5% of all liposarcomas. PLPS is an aggressive cancer that exhibits frequent local recurrence and metastasis, with an overall 5-year survival rate of ~ 60%. Owing to the lack of effective treatment options in inoperable conditions and resistance to chemotherapeutics, novel therapies are required to treat PLPS. Although patient-derived cell lines are a critical tool for basic and pre-clinical research, only one PLPS cell line is reportedly available for analysis. A paucity of adequate cell line hinders the progress of research and treatments of PLPS. Thus, we aimed to establish and characterize a novel patient-derived cell line for PLPS. Using surgically resected tumor tissue from a 71-year-old male patient, we established the NCC-PLPS1-C1 cell line. The cells were maintained for more than 8 months and passaged ~ 40 times in the tissue culture condition. NCC-PLPS1-C1 cells were characterized by multiple genetic deletions and showed rapid growth, spheroid formation, and invasive potential. The NCC-PLPS1-C1 cells and the original tumor tissue shared similar kinase activity profiles for FES and PDGFR-β. NCC-PLPS1-C1 constantly proliferated, being suitable for the screening of anti-cancer drugs. A screen for the anti-proliferative effects of anti-cancer drugs on NCC-PLPS1-C1 cells showed a significant response for bortezomib, gemcitabine, romidepsin, topotecan, and vinblastine. In conclusion, NCC-PLPS1-C1 cells represent a useful tool for basic and pre-clinical studies related to PLPS, especially high-throughput drug screening. Keywords Pleomorphic liposarcoma · PLPS · Patient-derived cell line · High-throughput screening · Primary tumor
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13577-020-00457-0) contains supplementary material, which is available to authorized users. * Tadashi Kondo [email protected] 1
Division of Rare Cancer Research, National Cancer Center Research Institute, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo 104‑0045, Japan
2
Division of Diagnostic Pathology, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
3
Division of Hepato‑Biliary‑Pancreatic Surgery, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
4
Division of Musculoskeletal Oncology and Orthopaedic Surgery, Tochigi Cancer Center, 4‑9‑13 Yohnan, Utsunomiya, Tochigi 320‑0834, Japan
Pleomorphic liposarcoma (PLPS) is a rare, high-grade subtype of liposarcoma [1], histologically characterized by th
Data Loading...
